Modulation of autocrine TNF-α-stimulated matrix metalloproteinase 9 (MMP-9) expression by mitogenactivated protein kinases in THP-1 monocytic cells [PDF]
, 2006 Matrix metalloproteinase 9 (MMP-9) is implicated in various physiological processes by its ability to degrade the extracellular matrix (ECM) and process multiple regulatory proteins. Normally, MMP-9 expression is tightly controlled in cells. Sustained or
Helmut Kolb +9 more
core +1 more source
Theorizing immune inhibition and TNF inhibitors from the autoimmune
Recerca: Revista de Pensament i Anàlisi, 2022 This article analyses the biochemical object of tnf inhibitors from the perspective of living with an autoimmune disease. The author tries to tease out how the concept of immune inhibition is used in tandem with the biochemical object of tnf inhibitors ...
Ohad Ben Shimon
doaj +1 more source
Manifestation of palmoplantar pustulosis during or after infliximab therapy for plaque-type psoriasis : report on five cases [PDF]
, 2008 Infliximab is a monoclonal antibody directed against TNF-alpha. It has been approved for use in rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, psoriatic arthritis and plaque-type psoriasis.
Krüger, Ullrich +13 more
core +1 more source
SNPs previously associated with therapeutic response to TNF inhibitors.
, 2022 SNPs previously associated with therapeutic response to TNF inhibitors.
Pingxing Xie (290131) +9 more
core +1 more source
BASELINE INFLAMMATORY MARKERS AND DISEASE ACTIVITY INDICES PREDICT TAPERING OF BIOLOGIC AGENTS IN ANKYLOSING SPONDYLITIS [PDF]
Romanian Journal of Rheumatology, 2018 Rationale. Clinicians need to have evidence-based information regarding the feasibility of tapering biologics in ankylosing spondylitis (AS). Objective. The study aims to identify significant predictors of tapering in clinical practice.
Marius Trandafir +5 more
doaj +1 more source
Epoxysuccinyl peptide-derived cathepsin B inhibitors: Modulating membrane permeability by conjugation with the C-terminal heptapeptide segment of penetratin [PDF]
, 2002 Schaschke N, Deluca D, Assfalg-Machleidt I, Hohneke C, Sommerhoff CP, Machleidt W. Epoxysuccinyl peptide-derived cathepsin B inhibitors: Modulating membrane permeability by conjugation with the C-terminal heptapeptide segment of penetratin.
Schaschke, Norbert +10 more
core +1 more source
, 2020 Use of each TNF inhibitor in patients with RA or AS since the approval of TNF inhibitors: Numbers of users of each TNF inhibitor with RA or AS since the approval of TNF inhibitors.
Seul Gi Im (4902652) +7 more
core +1 more source
PLoS ONE, 2016 BackgroundsPatients who develop an active tuberculosis infection during tumor necrosis factor (TNF) inhibitor treatment typically discontinue TNF inhibitor and receive standard anti-tuberculosis treatment.
Hye Won Kim +18 more
doaj +1 more source
The Saudi Journal of Gastroenterology, 2020 Background/Aim: Tumor necrosis factor inhibitors (TNFi) have become the mainstay of treatment in moderate-to-severe cases of inflammatory bowel disease (IBD). Neutropenia has been reported in patients receiving TNFi for IBD and other diseases.
Dimah AlAskar +4 more
doaj +1 more source
EFFICACY DIFFERENCES BETWEEN CLASSICAL AND BIOLOGICAL TREATMENT IN ANKYLOSING SPONDYLITIS [PDF]
Romanian Journal of Rheumatology, 2016 Objectives. The study aims at comparing classical and biological treatment of ankylosing spondylitis (AS) in terms of efficacy and to determine which treatment type is a significant predictor of low disease activity in a real life clinical situation ...
Claudiu Popescu +3 more
doaj +1 more source